TY - JOUR T1 - Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 4907 LP - 4912 DO - 10.21873/anticanres.15996 VL - 42 IS - 10 AU - TAKURO OKADA AU - TAKASHI MATSUKI AU - CHIHIRO FUSHIMI AU - ISAKU OKAMOTO AU - HIROKI SATO AU - TAKAHITO KONDO AU - KUNIHIKO TOKASHIKI AU - TATSUYA ITO AU - TATSUO MASUBUCHI AU - YUICHIRO TADA AU - KOUKI MIURA AU - KENJI HANYU AU - GO OMURA AU - HIDEKI TAKAHASHI AU - TAKU YAMASHITA AU - NOBUHIKO ORIDATE AU - KIYOAKI TSUKAHARA Y1 - 2022/10/01 UR - http://ar.iiarjournals.org/content/42/10/4907.abstract N2 - Background/Aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC. Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups. Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively). Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC. ER -